This is a past event. Registration is closed. View other NewYorkBIO events.
Registration and Networking
Welcome Remarks
Jennifer Hawks Bland•Andy Berglund
  • Jennifer Hawks Bland (Chief Executive Officer at NewYorkBIO)

    Jennifer Hawks Bland

    Chief Executive Officer at NewYorkBIO
  • Andy Berglund (Director of The RNA Institute | University at Albany)

    Andy Berglund

    Director of The RNA Institute | University at Albany
SupreMEtric Pitch Presentation
Alexis Weber

SupreMEtric LLC is developing the first universal, patented method for non-destructive, confirmatory identification of all main bodily fluids in biological evidence revealed at crime scenes for law enforcement and crime lab personnel.

  • Alexis Weber

    Alexis Weber

AlbaNYlabs Pitch Presentation
Sumanta Goswami

AlbaNYlabs is an NYCOQ-ED virology laboratory in Albany, NY. Both independently and in collaboration with NYSDOH Wadsworth center we have developed molecular assays that help identify replicative and potentially infectious viruses. Something that no other molecular assay can do. We have patent protection for one such assay for SARS-CoV-2 in collaboration with NYSDOH and are working on several more assays. This is a disruptive technology that targets the viral disease diagnosis market which is currently estimated to be at a value of US$ 18,560.5 Mn at the end of 2022 and expected to reach a value of US$ 30,046.1 Mn by 2030 with a significant CAGR of 6.2% in the USA.

  • Sumanta Goswami (Founder and CEO of AlbaNYlabs LLC)

    Sumanta Goswami

    Founder and CEO of AlbaNYlabs LLC
SPU Optics Pitch Presentation
Xiaoxu Sean Lin

SPU Optics Inc (SPU) is an early-stage company operated in Orange County, New York. SPU has the exclusive license of SpectroChip technology which was developed in Taiwan by SpectroChips Inc. With this breakthrough technologies, SPU provides high performance spectrometer-on-chip modules as core optical components to various optical instruments. Our SpectroChip/SPU devices can be designed for various spectral ranges, from UV to infrared, allowing for versatility in applications across different industries, including point-of-care testing, algae bloom detection, water quality in-situ sensing and monitoring, end-point detection in semiconductor industrial processing, etc. SPU aims to revolutionize spectral sensing and measurement, to empower individuals with rapid, accurate and decentralized testing for improved health and safety, to provide real-time in-situ precision measurement and monitoring for industrial production and environmental protection.

  • Xiaoxu Sean Lin (President at SPU Optics Inc)

    Xiaoxu Sean Lin

    President at SPU Optics Inc
sxRNA Technologies Pitch Presentation
Scott Tenenbaum, PhD

sxRNA Tech is a SUNY-Albany spin out specializing in making RNA-based therapeutics better. We do this by engineering customized RNA nanoswitches, which can make any RNA-drug become tissue specific. This patented approach permits targeted therapy with cellular precision and is being used to develop cancer, viral and senloytic drugs.

  • Scott Tenenbaum, PhD (CEO/President of sxRNA Tech)

    Scott Tenenbaum, PhD

    CEO/President of sxRNA Tech
Networking Break
Fireside Chat
Parthiban Rajasekaran, PhD•Lucie Rochard, PhD•Patrick Nelson
  • Parthiban Rajasekaran, PhD (Innovation Lead at Sanofi)

    Parthiban Rajasekaran, PhD

    Innovation Lead at Sanofi
  • Lucie Rochard, PhD (External Engagement Program Lead for R&D at Sanofi)

    Lucie Rochard, PhD

    External Engagement Program Lead for R&D at Sanofi
  • Patrick Nelson (Business Development Associate at SUNY RF)

    Patrick Nelson

    Business Development Associate at SUNY RF
Apheon Bioscience Pitch Presentation
William Belden

Apheon Bioscience specializes in research and development to support life sciences research through recombinant molecular biology technologies. Apheon Bioscience is committed to helping large and small organizations identify novel disease biomarkers to advance first-in-class immunotherapies. Apheon Bioscience offers affinity-based tumor antigen and biomarker discovery services that simultaneously provide therapeutic lead compounds. Other areas of research include the development of recombinant immune-particles to enhance complex immunoselection procedures and for precision diagnostics. We are also utilizing our platform for synthetic biology applications by creating novel abzyme (antibody-enzymes) capable of boosting catalytic enzymatic activity. We offer all our goods and services to assist academic laboratories and life sciences companies. Our mission is to streamline and boost research productivity in a cost-effective manner to help drive discovery. We welcome partnerships to develop immunotherapies for diseases with unmet medical needs. Our affinity-based antibody development platform profiles disease states based on antigenicity and provides both the biomarker target and corresponding therapeutic lead all-in-one. Lead compounds can be reversed engineered into recombinant human monoclonal antibodies, CAR-T therapy, or converted into antibody drug conjugates (ADC). The platform can also be deployed for precision medicine serving as a diagnostic to guide combination treatment decisions.

  • William Belden (President, CSO and Professor Emeritus at Apheon Bioscience)

    William Belden

    President, CSO and Professor Emeritus at Apheon Bioscience
ITrakNeuro Pitch Presentation

ITrakNeuro develops software and hardware that uses deep learning artificial intelligence to help neurosurgeons and health care providers identify and treat neuropathologies and vascular issues in the brain.

Company Presentation 7
Repeat RNA Therapeutics Pitch Presentation
John Douglas Cleary, PhD

Company Description – Repeat RNA Therapeutics (RRTx) is an early-stage startup focused on a drug discovery and development pipeline that targets the family of 50+ devastating diseases caused by expansion RNAs. While these diseases affect over 5% of the population, they universally lack effective disease modifying therapies, are difficult to diagnose, and result in long-lasting illness and mortality. Using our selective RNA Repeat Reduction platform technology we identify and develop new molecules and genetic targets that selectively reduce the toxic repeat RNAs which are the root cause of repeat expansion diseases. Complementing our therapeutic pipeline is deep knowledge of disease mechanism, biomarkers, and clinical trial design for repeat disorders. Our expertise, assets, and technology are used to support an informed transition of RRTx’s drugs out of the lab and into the clinical trial space.

  • John Douglas Cleary, PhD (Chief Operating Officer at Repeat RNA Therapeutics Inc)

    John Douglas Cleary, PhD

    Chief Operating Officer at Repeat RNA Therapeutics Inc
Closing Remarks
Maria Pidgeon
  • Maria Pidgeon (Director of Economic Development, Entrepreneurship, and Industry Partnerships at University at Albany)

    Maria Pidgeon

    Director of Economic Development, Entrepreneurship, and Industry Partnerships at University at Albany
Reception

Please join us to close the day with refreshments and networking! During this reception, the winners of the Mini Pitch Day prizes will be announced.